STERIS plc (STE) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Devices CIK: 0001757898

Market Cap 21.56 Bn

P/E 30.26

P/S 3.70

Div. Yield 0.01

ROIC (Qtr) 0.08

Total Debt (Qtr) 1.90 Bn

Revenue Growth (1y) (Qtr) 9.16

Add ratio to table...

About

STERIS plc, recognized in the stock market as STER, is a major player in the development and provision of products and services that enhance patient care, with a strong focus on infection prevention. The company is structured into three primary business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. These segments enable STERIS to cater to a wide range of clients, including healthcare providers, medical device manufacturers, and pharmaceutical companies, across various countries and regions worldwide. The revenue...

STERIS plc, recognized in the stock market as STER, is a major player in the development and provision of products and services that enhance patient care, with a strong focus on infection prevention. The company is structured into three primary business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. These segments enable STERIS to cater to a wide range of clients, including healthcare providers, medical device manufacturers, and pharmaceutical companies, across various countries and regions worldwide.

The revenue generation for STERIS occurs through the sales of consumable products, services, and capital equipment. Its primary product offerings comprise cleaning chemistries, sterility assurance products, automated endoscope reprocessors, endoscopy accessories, instruments, washers, sterilizers, and other essential capital equipment for sterile processing departments and procedure rooms. Additionally, the company provides services such as equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, outsourced reprocessing, and capital equipment maintenance.

Within the healthcare industry, STERIS has established a formidable presence by offering a comprehensive range of products and services tailored for healthcare providers. The Healthcare segment focuses on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites, providing infection prevention consumables, capital equipment, repair of reusable procedural instruments, and outsourced instrument reprocessing services.

In the Applied Sterilization Technologies (AST) segment, STERIS supports medical device and pharmaceutical manufacturers with a global network of contract sterilization and laboratory testing facilities, integrated sterilization equipment, and control systems. This segment's services encompass sterilization modalities and an array of testing services that complement the manufacturing of single-use, sterile products.

The Life Sciences segment contributes significantly to the biopharmaceutical and medical device research and manufacturing facilities, particularly those focused on aseptic manufacturing. This segment's product portfolio spans pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical-grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high-purity water and pure steam generators.

As STERIS operates in a competitive landscape, it maintains its edge through long-term supply contracts, proprietary technology, and strong brand recognition. The company's customer base is diverse, encompassing healthcare providers, medical device manufacturers, and pharmaceutical companies.

To summarize, STERIS plc's brand names and trade names include STERIS, a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company operates in three reportable business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, offering a comprehensive range of products and services to healthcare providers, medical device manufacturers, and pharmaceutical companies. STERIS generates revenue through the sale of consumable products, services, and capital equipment, with a strong competitive position based on long-term supply contracts, proprietary technology, and brand recognition.

Investment thesis

Bull case

The company’s constant currency organic revenue growth of 8% in Q3, combined with a 7%–8% guidance for FY26, signals a solid top‑line trajectory that market participants appear to undervalue. Despite tariffs and inflation, the firm delivered 11% growth in healthcare services and 9% growth in AST services, indicating resilience in core business segments. More importantly, the life sciences division posted a 103% jump in capital equipment revenue and maintains a backlog exceeding $100 million, reflecting robust demand that is not yet fully priced into the equity. These dynamics, coupled with the firm’s disciplined cost discipline—evidenced by a 40‑basis‑point EBIT margin decline offset by operating expense control—suggest that the market may be overlooking future earnings momentum. {bullet} Capital equipment plays a pivotal role in both healthcare and life sciences, and the company’s statement that its products are treated like a utility underscores their necessity for hospital capacity expansion. The firm’s commitment to a more integrated go‑to‑market model in EMEA, coupled with the strategic acquisition of channel and bolt‑on capabilities, positions it to capture a growing share of global sterilization services. The firm also highlighted the potential upside from the recent ASC shift, noting that ambulatory surgery centers require increased sterilization and disinfection support, a niche where the company has a strong foothold. This confluence of market expansion drivers—ASC growth, EMEA penetration, and capital equipment demand—provides a hidden catalyst that management has not fully amplified, presenting an undervalued growth engine. {bullet} Tariff exposure, while a short‑term headwind, is being actively managed through supply‑chain diversification and productivity initiatives, as detailed in the Q&A. The company has already incurred $16 million in tariff impact in Q3 and expects $55 million for FY26, yet it asserts it can offset most of this cost through shifting product movements, negotiating alternative suppliers, and operational efficiencies. These mitigation measures, combined with the firm’s low gross debt/EBITDA of 1.2 and healthy free‑cash‑flow generation of $7.4 billion, provide a solid balance sheet that can absorb the tariff shock without materially eroding long‑term profitability. Therefore, the market may be underestimating the company’s capacity to neutralize tariff costs and sustain margin health. {bullet} The firm’s outlook for FY27, while not explicitly quantified, suggests no material downside in the near term, with the management team indicating that macro conditions remain favorable. The backlog in capital equipment and the firm’s disciplined approach to small‑to‑mid‑size acquisitions demonstrate a strategic focus on sustainable, low‑leverage expansion. Moreover, the company’s emphasis on maintaining the current $375 million capex level signals confidence that its existing capital budget is sufficient to support ongoing demand. Together, these factors imply that the company could maintain or even accelerate its 7%–11% growth rate beyond FY26, a trajectory that the market is not fully pricing in. {bullet} Finally, the firm’s operational resilience, evidenced by its ability to sustain high single‑digit organic revenue growth and double‑digit earnings growth in the face of tariff and inflation pressures, suggests a robust moat that can withstand competitive and regulatory pressures. The consistent focus on margin preservation—through price improvements, volume expansion, and efficient cost management—ensures that profitability can be maintained even as growth continues. By keeping its leverage low and cash flows strong, the company is positioned to capitalize on future opportunities, whether through organic growth or selective acquisitions. These attributes collectively argue that the equity is undervalued relative to its future upside potential.

The company’s constant currency organic revenue growth of 8% in Q3, combined with a 7%–8% guidance for FY26, signals a solid top‑line trajectory that market participants appear to undervalue. Despite tariffs and inflation, the firm delivered 11% growth in healthcare services and 9% growth in AST services, indicating resilience in core business segments. More importantly, the life sciences division posted a 103% jump in capital equipment revenue and maintains a backlog exceeding $100 million, reflecting robust demand that is not yet fully priced into the equity. These dynamics, coupled with the firm’s disciplined cost discipline—evidenced by a 40‑basis‑point EBIT margin decline offset by operating expense control—suggest that the market may be overlooking future earnings momentum. {bullet} Capital equipment plays a pivotal role in both healthcare and life sciences, and the company’s statement that its products are treated like a utility underscores their necessity for hospital capacity expansion. The firm’s commitment to a more integrated go‑to‑market model in EMEA, coupled with the strategic acquisition of channel and bolt‑on capabilities, positions it to capture a growing share of global sterilization services. The firm also highlighted the potential upside from the recent ASC shift, noting that ambulatory surgery centers require increased sterilization and disinfection support, a niche where the company has a strong foothold. This confluence of market expansion drivers—ASC growth, EMEA penetration, and capital equipment demand—provides a hidden catalyst that management has not fully amplified, presenting an undervalued growth engine. {bullet} Tariff exposure, while a short‑term headwind, is being actively managed through supply‑chain diversification and productivity initiatives, as detailed in the Q&A. The company has already incurred $16 million in tariff impact in Q3 and expects $55 million for FY26, yet it asserts it can offset most of this cost through shifting product movements, negotiating alternative suppliers, and operational efficiencies. These mitigation measures, combined with the firm’s low gross debt/EBITDA of 1.2 and healthy free‑cash‑flow generation of $7.4 billion, provide a solid balance sheet that can absorb the tariff shock without materially eroding long‑term profitability. Therefore, the market may be underestimating the company’s capacity to neutralize tariff costs and sustain margin health. {bullet} The firm’s outlook for FY27, while not explicitly quantified, suggests no material downside in the near term, with the management team indicating that macro conditions remain favorable. The backlog in capital equipment and the firm’s disciplined approach to small‑to‑mid‑size acquisitions demonstrate a strategic focus on sustainable, low‑leverage expansion. Moreover, the company’s emphasis on maintaining the current $375 million capex level signals confidence that its existing capital budget is sufficient to support ongoing demand. Together, these factors imply that the company could maintain or even accelerate its 7%–11% growth rate beyond FY26, a trajectory that the market is not fully pricing in. {bullet} Finally, the firm’s operational resilience, evidenced by its ability to sustain high single‑digit organic revenue growth and double‑digit earnings growth in the face of tariff and inflation pressures, suggests a robust moat that can withstand competitive and regulatory pressures. The consistent focus on margin preservation—through price improvements, volume expansion, and efficient cost management—ensures that profitability can be maintained even as growth continues. By keeping its leverage low and cash flows strong, the company is positioned to capitalize on future opportunities, whether through organic growth or selective acquisitions. These attributes collectively argue that the equity is undervalued relative to its future upside potential.

Bear case

The company’s reliance on capital equipment, which constitutes a large portion of its revenue mix, exposes it to significant cyclical risk that the market may be overlooking. The Q3 capital equipment revenue surged 103%, yet the firm cautioned that this spike was partly due to an uptick in metals pricing, which may not be sustainable once the temporary pricing premium erodes. Moreover, the firm acknowledged that the fourth‑quarter capital equipment performance is expected to be weaker than the third quarter, signalling a potential slowdown in demand. If this slowdown materializes, the company could see its top‑line growth falter, thereby undermining the bullish outlook. {bullet} Tariff costs, which have risen to an annual run rate of $55 million, are a persistent drag on profitability and represent an unspoken risk. The Q&A revealed that tariffs were already impacting the third quarter and are projected to increase further in the fourth quarter, yet management remains optimistic about offsetting these costs. The firm’s current mitigation strategy relies heavily on supply‑chain adjustments and productivity gains, but the effectiveness of these measures is uncertain, especially if tariff rates climb or if the firm is forced to adjust product mix towards higher‑tariff items such as metals. Should the tariffs continue to rise, the company’s EBIT margin—already down 40 basis points from the prior year—could erode further, creating a pressure on earnings that the market may not fully appreciate. {bullet} While the company projects a strong outlook for FY27, it also signals uncertainty regarding the macroeconomic environment, particularly in the healthcare and life sciences sectors. Management’s cautious tone during the Q&A—highlighting a slowdown in the second half and a more modest growth outlook for Q4—indicates that the firm does not fully trust the current momentum. Additionally, regulatory changes, such as CMS proposals affecting inpatient-only lists and potential API relocation initiatives, could alter the demand dynamics for the company’s services. If these regulatory shifts reduce surgical volume or shift purchasing power away from the firm’s products, the company could experience a decline in revenue growth, a risk that may be underestimated by the market. {bullet} The company’s debt position, while manageable at a gross debt/EBITDA ratio of 1.2, is at risk of tightening if capital expenditures rise or if free cash flow is impacted by tariff costs or lower-than‑expected revenue. Management admitted that the firm has not pursued significant acquisitions in recent years and has a conservative approach to expansion, which could limit the firm’s ability to adapt quickly to changing market conditions. In a highly competitive industry where peers may execute more aggressive M&A strategies or innovate more rapidly, the company’s slower pace could result in lost market share. This strategic inertia presents a risk that could erode long‑term growth prospects and is not fully reflected in current valuations. {bullet} Finally, the company’s dependence on pricing power—illustrated by a 200‑basis‑point price increase contributing to organic revenue growth—could be challenged by heightened price sensitivity in the market. The Q&A indicated that increased tariffs and inflation have offset the positive effects of price and productivity gains, narrowing gross margins to 43.9% from 44.6% in the prior year. If competitors begin to offer lower‑priced alternatives or if customers renegotiate contracts in response to higher input costs, the firm could face margin compression. The potential for price erosion, combined with the aforementioned tariff and demand risks, could limit the upside potential and may be undervalued by the market.

The company’s reliance on capital equipment, which constitutes a large portion of its revenue mix, exposes it to significant cyclical risk that the market may be overlooking. The Q3 capital equipment revenue surged 103%, yet the firm cautioned that this spike was partly due to an uptick in metals pricing, which may not be sustainable once the temporary pricing premium erodes. Moreover, the firm acknowledged that the fourth‑quarter capital equipment performance is expected to be weaker than the third quarter, signalling a potential slowdown in demand. If this slowdown materializes, the company could see its top‑line growth falter, thereby undermining the bullish outlook. {bullet} Tariff costs, which have risen to an annual run rate of $55 million, are a persistent drag on profitability and represent an unspoken risk. The Q&A revealed that tariffs were already impacting the third quarter and are projected to increase further in the fourth quarter, yet management remains optimistic about offsetting these costs. The firm’s current mitigation strategy relies heavily on supply‑chain adjustments and productivity gains, but the effectiveness of these measures is uncertain, especially if tariff rates climb or if the firm is forced to adjust product mix towards higher‑tariff items such as metals. Should the tariffs continue to rise, the company’s EBIT margin—already down 40 basis points from the prior year—could erode further, creating a pressure on earnings that the market may not fully appreciate. {bullet} While the company projects a strong outlook for FY27, it also signals uncertainty regarding the macroeconomic environment, particularly in the healthcare and life sciences sectors. Management’s cautious tone during the Q&A—highlighting a slowdown in the second half and a more modest growth outlook for Q4—indicates that the firm does not fully trust the current momentum. Additionally, regulatory changes, such as CMS proposals affecting inpatient-only lists and potential API relocation initiatives, could alter the demand dynamics for the company’s services. If these regulatory shifts reduce surgical volume or shift purchasing power away from the firm’s products, the company could experience a decline in revenue growth, a risk that may be underestimated by the market. {bullet} The company’s debt position, while manageable at a gross debt/EBITDA ratio of 1.2, is at risk of tightening if capital expenditures rise or if free cash flow is impacted by tariff costs or lower-than‑expected revenue. Management admitted that the firm has not pursued significant acquisitions in recent years and has a conservative approach to expansion, which could limit the firm’s ability to adapt quickly to changing market conditions. In a highly competitive industry where peers may execute more aggressive M&A strategies or innovate more rapidly, the company’s slower pace could result in lost market share. This strategic inertia presents a risk that could erode long‑term growth prospects and is not fully reflected in current valuations. {bullet} Finally, the company’s dependence on pricing power—illustrated by a 200‑basis‑point price increase contributing to organic revenue growth—could be challenged by heightened price sensitivity in the market. The Q&A indicated that increased tariffs and inflation have offset the positive effects of price and productivity gains, narrowing gross margins to 43.9% from 44.6% in the prior year. If competitors begin to offer lower‑priced alternatives or if customers renegotiate contracts in response to higher input costs, the firm could face margin compression. The potential for price erosion, combined with the aforementioned tariff and demand risks, could limit the upside potential and may be undervalued by the market.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	177.36 Bn	27.31	4.00	12.93 Bn
2	SYK	Stryker Corp	124.60 Bn	38.40	4.96	15.86 Bn
3	MDT	Medtronic plc	109.93 Bn	23.82	3.10	28.07 Bn
4	BSX	Boston Scientific Corp	93.15 Bn	31.94	4.64	11.44 Bn
5	EW	Edwards Lifesciences Corp	46.49 Bn	43.68	7.66	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.40 Bn	25.00	1.46	9.41 Bn
7	DXCM	Dexcom Inc	24.14 Bn	28.78	5.18	-
8	STE	STERIS plc	21.56 Bn	30.26	3.70	1.90 Bn

Research Tools

STERIS plc (NYSE: STE)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Peer comparison

Research Tools

STERIS plc (NYSE: STE)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password